PT - JOURNAL ARTICLE AU - Brian Stagg AU - Joshua D Stein AU - Felipe A Medeiros AU - Mollie Cummins AU - Kensaku Kawamoto AU - Rachel Hess TI - Interests and needs of eye care providers in clinical decision support for glaucoma AID - 10.1136/bmjophth-2020-000639 DP - 2021 Jan 01 TA - BMJ Open Ophthalmology PG - e000639 VI - 6 IP - 1 4099 - http://bmjophth.bmj.com/content/6/1/e000639.short 4100 - http://bmjophth.bmj.com/content/6/1/e000639.full SO - BMJ Open Ophth2021 Jan 01; 6 AB - Objective To study whether clinicians who treat glaucoma are interested in using clinical decision support (CDS) tools for glaucoma, what glaucoma clinical decisions they feel would benefit from CDS, and what characteristics of CDS design they feel would be important in glaucoma clinical practice.Methods and analysis Working with the American Glaucoma Society, the Utah Ophthalmology Society and the Utah Optometric Association, we identified a group of clinicians who care for patients with glaucoma. We asked these clinicians about interest in CDS, what glaucoma clinical decisions would benefit from CDS, and what characteristics of CDS tool design would be important in glaucoma clinical practice.Results Of the 105 clinicians (31 optometrists, 10 general ophthalmologists and 64 glaucoma specialists), 93 (88.6%) were either ‘definitely’ or ‘probably’ interested in using CDS for glaucoma. There were no statistically significant differences in interest between clinical specialties (p=0.12), years in practice (p=0.85) or numbers of patients seen daily (p=0.99). Identifying progression of glaucoma was the clinical decision the largest number of clinicians felt would benefit from CDS (104/105, 99.1%). An easy to use interface was the CDS characteristic the largest number of clinicians felt would be ‘very important’ (93/105, 88.6%).Conclusion Of this group of clinicians who treat glaucoma, 88.6% were interested in using CDS for glaucoma and 99.1% felt that identification of glaucomatous progression could benefit from CDS. This level of interest supports future work to develop CDS for glaucoma.